Search results
Novartis AG (NYSE:NVS) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 months agoNovartis AG (NYSE:NVS) Q4 2023 Earnings Call Transcript January 31, 2024 Novartis AG misses on...
Novartis AG's Dividend Analysis
GuruFocus.com via Yahoo Finance· 2 months agoNovartis AG (NYSE:NVS) recently announced a dividend of $3.78 per share, payable on a date yet to be announced, with the ex-dividend date set for...
Novartis Is Tracking Well Above the Industry
GuruFocus.com via Yahoo Finance· 2 weeks agoNovartis AG (NYSE:NVS) is one of the largest pharmaceutical companies in the world, many of whose drugs are "gold standards" in the treatment of cancer,...
Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug
Benzinga via Yahoo Finance· 1 year agoNovartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of...
Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster Brands
Benzinga via Yahoo Finance· 2 years agoNovartis AG (NYSE: NVS) has revealed insights into the updated company strategy. The company said...
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
Benzinga via Yahoo Finance· 4 months agoNovartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK)...
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Benzinga via Yahoo Finance· 1 year agoNovartis AG (NYSE: NVS) has reported Q4 core EPS of $1.52 compared to $1.40 a year ago, beating the...
Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent...
Benzinga via Yahoo Finance· 11 months agoNovartis AG's (NYSE: NVS) generics unit Sandoz tells investors it can add $3 billion in annual sales...
Novartis Appoints Merck Executive As Research Head
Benzinga via Yahoo Finance· 2 years agoNovartis AG (NYSE: NVS) has appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay...
Novartis Announces $250M In R&D Funding For Neglected Tropical Diseases, Malaria
Benzinga via Yahoo Finance· 2 years agoNovartis AG (NYSE: NVS) is pledging $250 million into R&D for new treatments of neglected tropical...
